爱必妥联合放化or化疗食道癌ASCO.pptVIP

Methods: Main inclusion criteria were: stage III squamous cell or adenocarcinoma of the esophagus or gastroesophageal junction; WHO PS 0-1; age 18-80 years; weight loss 15% in the last 6 months. Patients (pts) received 2 cycles of induction FOLFOX plus cetuximab therapy, then 50.4Gy of radiation with FOLFOX plus cetuximab. Tumor evaluation was performed at the end of CRT. Primary end-point was the overall response rate (ORR, RECIST). Results: male/female 24/12, median age 63 years (23-79), PS 0/1/ND 22/13/1, squamous/adenocarcinoma/undifferentiated 20/15/1; esophagus/cardia 32/4; median da